Tina Young Poussaint

Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial

Jason Fangusaro, Arzu Onar‐Thomas, Tina Young Poussaint et al. · The Lancet Oncology · 2019 · 502 citations · Full text

Medicine, Oncology, Pediatrics +16

Neurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome

Kerri L. LaRovere, Becky J. Riggs, Tina Young Poussaint et al. · JAMA Neurology · 2021 · 404 citations · Full text

Medicine, Neurology, Pediatrics +13

A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study

Anuradha Banerjee, Regina I. Jakacki, Arzu Onar‐Thomas et al. · Neuro-Oncology · 2017 · 320 citations · Full text

Medicine, Oncology, Pharmacology +17

Lack of Efficacy of Bevacizumab Plus Irinotecan in Children With Recurrent Malignant Glioma and Diffuse Brainstem Glioma: A Pediatric Brain Tumor Consortium Study

Sridharan Gururangan, Susan Chi, Tina Young Poussaint et al. · Journal of Clinical Oncology · 2010 · 194 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: A Pediatric Brain Tumor Consortium report1

Ian F. Pollack, Regina I. Jakacki, Susan M. Blaney et al. · Neuro-Oncology · 2007 · 191 citations · Full text

Medicine, Oncology, Pharmacology +13